Jump to main content
Jump to site search


Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor

Author affiliations

Abstract

Cyclin-dependent kinases have emerged as important targets for cancer therapy. HSD992, containing a novel scaffold based on the tetrahydro-3H-pyrazolo[4,3-a]phenanthridine core, inhibits CDK2/3 but not other CDKs and also potently inhibits several cancer cell lines.

Graphical abstract: Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 Feb 2018, accepted on 29 Mar 2018 and first published on 29 Mar 2018


Article type: Communication
DOI: 10.1039/C8CC01154K
Citation: Chem. Commun., 2018, Advance Article
  •   Request permissions

    Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor

    C. Opoku-Temeng, N. Dayal, D. E. Hernandez, N. Naganna and H. O. Sintim, Chem. Commun., 2018, Advance Article , DOI: 10.1039/C8CC01154K

Search articles by author

Spotlight

Advertisements